H. Lundbeck Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de H. Lundbeck de 9.9% y 2.1% por año respectivamente. Se prevé que el BPA crezca en un 10.1% al año. Se espera que la rentabilidad financiera sea de 15.3% en 3 años.

Información clave

9.9%

Tasa de crecimiento de los beneficios

10.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	14.8%
Tasa de crecimiento de los ingresos	2.1%
Rentabilidad financiera futura	15.3%
Cobertura de analistas	Good
Última actualización	10 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

LSE:0ND5 - Estimaciones futuras de los analistas y datos financieros pasados (DKK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	22,630	3,828	4,917	5,528	9
12/31/2025	21,859	3,409	4,499	5,244	10
12/31/2024	20,989	2,981	4,429	4,843	10
12/31/2023	19,912	2,290	3,579	4,080	N/A
9/30/2023	19,614	2,467	3,528	4,426	N/A
6/30/2023	19,381	2,479	3,523	4,457	N/A
3/31/2023	18,918	2,384	3,292	4,102	N/A
12/31/2022	18,246	1,916	2,699	3,519	N/A
9/30/2022	17,619	1,603	2,051	2,615	N/A
6/30/2022	16,913	1,236	1,744	2,313	N/A
3/31/2022	16,398	1,109	1,344	1,959	N/A
12/31/2021	16,299	1,318	1,660	2,272	N/A
9/30/2021	16,521	1,873	2,405	2,949	N/A
6/30/2021	16,971	1,965	2,379	2,912	N/A
3/31/2021	17,381	2,110	3,263	3,757	N/A
12/31/2020	17,672	1,581	3,359	3,837	N/A
9/30/2020	17,818	904	2,713	3,171	N/A
6/30/2020	17,490	1,242	2,910	3,354	N/A
3/31/2020	17,366	1,507	1,502	1,960	N/A
12/31/2019	17,036	2,313	2,165	2,609	N/A
9/30/2019	16,811	3,091	3,210	3,621	N/A
6/30/2019	17,309	3,395	2,736	3,462	N/A
3/31/2019	17,766	3,606	4,100	4,815	N/A
12/31/2018	18,117	3,907	5,277	5,981	N/A
9/30/2018	18,313	3,806	5,057	5,922	N/A
6/30/2018	18,028	3,627	5,368	6,197	N/A
3/31/2018	17,608	3,236	4,629	5,397	N/A
12/31/2017	17,234	2,624	3,320	4,045	N/A
9/30/2017	17,007	2,544	N/A	3,731	N/A
6/30/2017	16,607	1,988	N/A	3,551	N/A
3/31/2017	16,075	1,612	N/A	3,420	N/A
12/31/2016	15,634	1,211	N/A	3,126	N/A
9/30/2016	15,202	290	N/A	4,158	N/A
6/30/2016	14,923	-1,289	N/A	2,755	N/A
3/31/2016	14,801	-5,427	N/A	936	N/A
12/31/2015	14,594	-5,694	N/A	197	N/A
9/30/2015	14,108	-5,879	N/A	-1,330	N/A
6/30/2015	13,625	-4,615	N/A	-464	N/A
3/31/2015	13,444	-565	N/A	1,379	N/A
12/31/2014	13,468	-153	N/A	1,610	N/A
9/30/2014	13,808	503	N/A	2,601	N/A
6/30/2014	14,181	765	N/A	2,095	N/A
3/31/2014	14,269	119	N/A	2,982	N/A
12/31/2013	15,258	855	N/A	3,760	N/A
9/30/2013	15,516	1,036	N/A	2,931	N/A
6/30/2013	15,574	1,195	N/A	3,214	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (9.9% al año) de 0ND5 es superior a la tasa de ahorro (1.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (9.9% al año) de 0ND5 crezcan menos que el mercado UK (12.2% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 0ND5 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (2.1% al año) de 0ND5 crezcan más despacio que el mercado de UK (3.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 2.1% al año) de 0ND5 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 0ND5 sea baja dentro de 3 años (15.3%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

H. Lundbeck Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Provides Earnings Guidance for the Year 2022

H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2020

H. Lundbeck A/S Revises Earnings Guidance for the Year 2020

Recent updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Key Executive recently bought kr.751k worth of stock

Dividend increased to kr.0.70

Full year 2023 earnings released: EPS: kr.2.31 (vs kr.1.93 in FY 2022)

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

H. Lundbeck A/S Common Stock to Be Deleted from OTC Equity

First quarter 2022 earnings released: EPS: kr.2.07 (vs kr.3.13 in 1Q 2021)

H. Lundbeck A/S Provides Earnings Guidance for the Year 2022

Less than half of directors are independent

H. Lundbeck A/S Completes Global Phase Iv, Randomized, Comparative Study Exploring the Role of Vortioxetine

H. Lundbeck A/S Appoints Joergornstein as Member of Lundbeck's Executive Management

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI

Less than half of directors are independent

Upcoming dividend of kr.2.00 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

H. Lundbeck A/S Proposes Dividend for the Year 2021

EU Commission Approves Vyepti[®] (Eptinezumab) for the Preventive Treatment of Migraine in Adults

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17

Third quarter 2021 earnings released: EPS kr.1.62 (vs kr.2.38 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr.1.90 (vs kr.2.93 in 2Q 2020)

First quarter 2021 earnings released: EPS kr.3.13 (vs kr.0.76 in 1Q 2020)

H. Lundbeck A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

H. Lundbeck A/S Announces New Study Finds That Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder

Independent Director has left the company

H. Lundbeck A/S Appoints Tarek Samad as Head of Research, Effective on May 1, 2021

Upcoming Dividend of kr.2.50 Per Share

H. Lundbeck A/S Announces Resignation of Henrik Andersen from Board

Full year 2020 earnings released: EPS kr.7.95 (vs kr.13.42 in FY 2019)

Revenue misses expectations

New 90-day high: kr.239

New 90-day high: kr.215

Rigshospitalet and Lundbeck Announce Partnership to Find New Ways to Treat Brain Diseases

Lundbeck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Eptinezumab for the Prevention of Migraine

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2020

H. Lundbeck A/S Revises Earnings Guidance for the Year 2020

Revenue beats expectations

Third quarter 2020 earnings released: EPS kr.2.38

New 90-day low: kr.177

New 90-day low: kr.196

OVATION Pharmaceuticals, Inc. acquired Buronil from H. Lundbeck A/S.

H. Lundbeck A/S Presents Positive Data from the Complete Study with Vortioxetine

New 90-day low - kr.208

Earnings released

New 90-day low - ø231

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento